Fujian Cosunter Pharmaceutical Co., Ltd. (SHE:300436)
China · Delayed Price · Currency is CNY 107.94
+5.92 (5.80%)
Feb 3, 2026, 2:55 PM CST
SHE:300436 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 427 | 437.48 | 413.32 | 379.76 | 370.01 | 368.38 |
Other Revenue | 3.98 | 3.98 | 9.4 | 6.01 | 0.43 | 0.11 |
| 430.98 | 441.46 | 422.71 | 385.77 | 370.44 | 368.49 | |
Revenue Growth (YoY) | -8.17% | 4.43% | 9.58% | 4.14% | 0.53% | -11.18% |
Cost of Revenue | 195.64 | 202.19 | 186.54 | 162.62 | 140.19 | 124.92 |
Gross Profit | 235.34 | 239.27 | 236.18 | 223.15 | 230.25 | 243.57 |
Selling, General & Admin | 324.94 | 311.75 | 304.71 | 262.65 | 234.7 | 190.63 |
Research & Development | 48.74 | 44.05 | 132.96 | 185.46 | 68.99 | 47.47 |
Other Operating Expenses | 25.83 | 7.65 | 8.8 | -0.58 | 6.85 | 6.08 |
Operating Expenses | 401.11 | 364 | 448.24 | 448.11 | 311.31 | 244.34 |
Operating Income | -165.78 | -124.74 | -212.07 | -224.96 | -81.06 | -0.77 |
Interest Expense | -33.92 | -35.55 | -35.03 | -10.59 | -9.13 | -8.94 |
Interest & Investment Income | 0.65 | 1.41 | 4.5 | 76.09 | 30.7 | 1.27 |
Earnings From Equity Investments | 1.56 | - | - | - | - | 12.46 |
Currency Exchange Gain (Loss) | 0 | 0 | 0 | -0.01 | 0 | 0.01 |
Other Non Operating Income (Expenses) | 0.68 | -0.05 | -0.23 | -3.06 | -0.11 | - |
EBT Excluding Unusual Items | -196.8 | -158.93 | -242.82 | -162.54 | -59.59 | 4.02 |
Gain (Loss) on Sale of Investments | -11 | -11 | -61.84 | - | - | - |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | -0.02 | - | -0.31 | -2.16 |
Asset Writedown | -46.79 | -39.77 | -0.22 | -0.88 | -1.32 | -0.02 |
Other Unusual Items | 52.8 | 45.27 | 6.87 | - | 15.54 | 13.51 |
Pretax Income | -201.77 | -164.41 | -298.03 | -163.42 | -45.69 | 15.35 |
Income Tax Expense | 15.84 | 8.06 | 76.87 | -22.86 | -11.53 | -1.18 |
Earnings From Continuing Operations | -217.61 | -172.47 | -374.9 | -140.57 | -34.16 | 16.53 |
Minority Interest in Earnings | 20.36 | 16.16 | 26.31 | 13.16 | -0.72 | -1.7 |
Net Income | -197.25 | -156.3 | -348.59 | -127.4 | -34.89 | 14.82 |
Net Income to Common | -197.25 | -156.3 | -348.59 | -127.4 | -34.89 | 14.82 |
Net Income Growth | - | - | - | - | - | 38.01% |
Shares Outstanding (Basic) | 159 | 159 | 159 | 159 | 149 | 140 |
Shares Outstanding (Diluted) | 159 | 159 | 159 | 159 | 149 | 140 |
Shares Change (YoY) | -0.01% | -0.00% | 0.06% | 6.54% | 6.43% | 0.24% |
EPS (Basic) | -1.24 | -0.98 | -2.19 | -0.80 | -0.23 | 0.11 |
EPS (Diluted) | -1.24 | -0.98 | -2.19 | -0.80 | -0.23 | 0.11 |
EPS Growth | - | - | - | - | - | 37.68% |
Free Cash Flow | -55.28 | -46.28 | -375.83 | -315.64 | -192.17 | -38.86 |
Free Cash Flow Per Share | -0.35 | -0.29 | -2.36 | -1.98 | -1.29 | -0.28 |
Gross Margin | 54.61% | 54.20% | 55.87% | 57.85% | 62.16% | 66.10% |
Operating Margin | -38.46% | -28.26% | -50.17% | -58.32% | -21.88% | -0.21% |
Profit Margin | -45.77% | -35.41% | -82.47% | -33.03% | -9.42% | 4.02% |
Free Cash Flow Margin | -12.83% | -10.48% | -88.91% | -81.82% | -51.88% | -10.54% |
EBITDA | -54.17 | -30.19 | -140.26 | -166.66 | -29.29 | 36.54 |
EBITDA Margin | -12.57% | -6.84% | -33.18% | -43.20% | -7.91% | 9.92% |
D&A For EBITDA | 111.61 | 94.55 | 71.81 | 58.3 | 51.77 | 37.31 |
EBIT | -165.78 | -124.74 | -212.07 | -224.96 | -81.06 | -0.77 |
EBIT Margin | -38.46% | -28.26% | -50.17% | -58.32% | -21.88% | -0.21% |
Revenue as Reported | 430.98 | 441.46 | 422.71 | - | 370.44 | 368.49 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.